

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, Box 1450, P.O. Box 1450, Alexandria, VA 22313-1450 on this day of May, 2004.

By _____

(Signature of person mailing)
Andrea E. Dorigo

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lee et al. :

APPLICATION NO.: 10/626,275 : Examiner:

FILING DATE: July 25, 2002 : Group Art Unit: 1614

TITLE: PRAMIPEXOLE ONCE-DAILY
DOSAGE FORM :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

Patent Application
Attorney Docket No. PC28017

A prompt and favorable response is earnestly solicited.

Date: 5/3/04

Respectfully submitted,


Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532


Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898

Patent Application
Attorney Docket No. PC28017

A prompt and favorable response is earnestly solicited.

Date: 5/3/04

Respectfully submitted,


Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) <i>MAY 05 2004</i>								ATTY. DOCKET NO. PC28017		SERIAL NO. 10/626,275				
								APPLICANT Lee et al.						
								FILING DATE July 25, 2002		GROUP 1614				
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
a)	6	2	7	7	8	7	5	8/21/01	Holman, Andrew J.	514	367			
b)	4	7	3	1	3	7	4	3/15/88	Griss et al.	514	367			
c)	0	9	1	5	7	3	5	2/7/02	Hedden et al.	424	488			
d)	6	0	5	6	9	7	7	5/2/00	Bhagwat et al.	424	488			
e)	5	4	7	2	7	1	2	12/5/95	Oshlack et al.	424	480			
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	f)	0	1	2	2	8	2	0	4/5/01	WO	A01N	43/78	YES	NO
	g)	9	9	1	6	4	4	2	4/8/99	WO	A61K			
	h)	9	9	0	9	0	6	6	2/25/99	WO	C08B	A61K		
	i)	9	9	4	5	9	2	4	9/16/99	WO	A61K			
	j)	0	0	5	9	4	7	7	10/12/00	WO	A61K			
	k)	9	7	0	7	7	5	2	2/13/97	WO	A61K			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	l)	Hubble et al. (1995), <i>Clinical Neuropharmacology</i> 18(4), 338–347												
	m)	Dooley & Markham (1998), <i>Drugs & Aging</i> 12(6), 495–514												
	n)	Biglan & Holloway (2002), <i>Expert Opinion on Pharmacotherapy</i> 3(2), 197–210												
	o)	Wright et al. (1997), <i>Journal of Clinical Pharmacology</i> 37, 520–525												
	o)	United States Pharmacopeia 24th edition (2000) (USP 24), pp. 1941–1943												
	q)	Colosimo & De Michele (1999), <i>European Journal of Neurology</i> 6(1), 1–21												
EXAMINER				DATE CONSIDERED										
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														